Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2011

01.04.2011 | Original Article

Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients

verfasst von: Hiroko Masuda, Norikazu Masuda, Yoshinori Kodama, Masami Ogawa, Michiko Karita, Jun Yamamura, Kazunori Tsukuda, Hiroyoshi Doihara, Shinichiro Miyoshi, Masayuki Mano, Shoji Nakamori, Toshimasa Tsujinaka

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Triple-negative breast cancers (TNBCs) do not derive benefit from molecular-targeted treatments such as endocrine therapy or anti-HER2 therapy because they lack those molecular targets. On the other hand, TNBCs have been shown to respond to neoadjuvant chemotherapy (NAC). In this study, we analyzed TNBC patients who were treated with NAC at Osaka National Hospital over a recent 5-year period to clarify the predictive factors for NAC and prognostic factors.

Patients and methods

Thirty-three TNBC patients underwent sequential NAC with anthracycline (FEC100: 5FU 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2/q3w, 4 courses) and taxanes (paclitaxel 80 mg/m2/qw, 12 courses or docetaxel 75 mg/m2/q3w, 4 courses) from May 2003 to July 2008. Pre-therapeutical and surgical specimens were studied for expressions of ER, PgR, HER-2, EGFR, cytokeratin 5/6, Ki-67, p53 and androgen receptor by immunohistochemistry (IHC). We analyzed clinicopathological factors and molecular markers in regard to the response to NAC and prognosis.

Results

Pathological complete response (pCR) was achieved in 12 TNBC patients (36%). The pCR rate in the basal-like phenotype was significantly lower than in the non-basal-like phenotype (23 vs. 64%, respectively: P = 0.02). High pre-operative expressions of Ki-67 (≥50%) and HER-2 (2+) were considered as predictive factors for a better response from NAC. Pre-operative Ki-67 expression showed a significant correlation with disease-free survival (DFS) and a lower expression of Ki-67 (<50%) after NAC was favorable for DFS among non-pCR patients.

Conclusions

A non-basal-like phenotype and higher expressions of Ki-67 and HER-2 (2+) were favorable factors for NAC. However, a higher expression of Ki-67 on the surgical specimen after NAC was also a poor prognostic factor.
Literatur
1.
Zurück zum Zitat Dawson SJ, Provenzano E, Caldas C (2009) Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45(Suppl 1):27–40PubMedCrossRef Dawson SJ, Provenzano E, Caldas C (2009) Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer 45(Suppl 1):27–40PubMedCrossRef
2.
Zurück zum Zitat Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32PubMedCrossRef Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32PubMedCrossRef
3.
Zurück zum Zitat Kreike B, van Kouwenhove M, Horlings H et al (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65 Kreike B, van Kouwenhove M, Horlings H et al (2007) Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9:R65
4.
Zurück zum Zitat Kuroda N, Ohara M, Inoue K et al (2009) The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma. Med Mol Morphol 42:128–131PubMedCrossRef Kuroda N, Ohara M, Inoue K et al (2009) The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma. Med Mol Morphol 42:128–131PubMedCrossRef
5.
Zurück zum Zitat Pintens S, Neven P, Drijkoningen M et al (2009) Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J Clin Pathol 62:624–628PubMedCrossRef Pintens S, Neven P, Drijkoningen M et al (2009) Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J Clin Pathol 62:624–628PubMedCrossRef
6.
Zurück zum Zitat Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triple negative Breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2301–2310CrossRef Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triple negative Breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15:2301–2310CrossRef
7.
Zurück zum Zitat Gluz O, Liedtke C, Gottschalk N et al (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20:1913–1927PubMedCrossRef Gluz O, Liedtke C, Gottschalk N et al (2009) Triple-negative breast cancer-current status and future directions. Ann Oncol 20:1913–1927PubMedCrossRef
8.
Zurück zum Zitat Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMed Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMed
9.
Zurück zum Zitat Scholl SM, Fourquet A, Asselain B et al (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomized trial:S6. Eur J Cancer 30A:645–652PubMedCrossRef Scholl SM, Fourquet A, Asselain B et al (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery: preliminary results of a randomized trial:S6. Eur J Cancer 30A:645–652PubMedCrossRef
10.
Zurück zum Zitat Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281PubMedCrossRef Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281PubMedCrossRef
11.
Zurück zum Zitat Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334PubMedCrossRef Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334PubMedCrossRef
12.
Zurück zum Zitat Abrial SC, Penault-Llorca F, Delva R et al (2005) High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94:255–263PubMedCrossRef Abrial SC, Penault-Llorca F, Delva R et al (2005) High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat 94:255–263PubMedCrossRef
13.
Zurück zum Zitat von Minckwitz G, Sinn HP, Raab G et al (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10:R30 von Minckwitz G, Sinn HP, Raab G et al (2008) Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 10:R30
14.
Zurück zum Zitat OgawaY Hai E, Matsumoto K et al (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13:431–435CrossRef OgawaY Hai E, Matsumoto K et al (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int J Clin Oncol 13:431–435CrossRef
15.
Zurück zum Zitat Berns EM, Foekens JA, Vossen R et al (2000) Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60:2155–2162PubMed Berns EM, Foekens JA, Vossen R et al (2000) Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60:2155–2162PubMed
16.
Zurück zum Zitat Assersohn L, Salter J, Powles TJ et al (2003) Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 82:113–123PubMedCrossRef Assersohn L, Salter J, Powles TJ et al (2003) Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat 82:113–123PubMedCrossRef
17.
Zurück zum Zitat Burcombe RJ, Makris A, Richman PI et al (2005) Evaluation of ER, PgR, HER2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92:147–155PubMedCrossRef Burcombe RJ, Makris A, Richman PI et al (2005) Evaluation of ER, PgR, HER2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92:147–155PubMedCrossRef
18.
Zurück zum Zitat Harvey JM, Clark GM, Osborne K et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed Harvey JM, Clark GM, Osborne K et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed
19.
Zurück zum Zitat Goldhirsh A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583CrossRef Goldhirsh A, Glick JH, Gelber RD et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583CrossRef
20.
Zurück zum Zitat Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685PubMedCrossRef Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685PubMedCrossRef
21.
Zurück zum Zitat Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer. Ann Oncol 20:1319–1329PubMedCrossRef Goldhirsch A, Ingle JN, Gelber RD et al (2009) Thresholds for therapies: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer. Ann Oncol 20:1319–1329PubMedCrossRef
22.
Zurück zum Zitat Wolff AC, Hammond MEH, Schwartz JN et al (2007) American society of clinical oncology/College of American pathologists guideline recommendations of human epidermal growth factor receptors 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef Wolff AC, Hammond MEH, Schwartz JN et al (2007) American society of clinical oncology/College of American pathologists guideline recommendations of human epidermal growth factor receptors 2 testing in breast cancer. J Clin Oncol 25:118–145PubMedCrossRef
23.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing and estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010 (Epub) Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/College of American pathologists guideline recommendations for immunohistochemical testing and estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010 (Epub)
24.
Zurück zum Zitat Pal SK, Mortimer J (2009) Triple-negative breast cancer: novel therapies and new directions. Maturitas 63:269–274PubMedCrossRef Pal SK, Mortimer J (2009) Triple-negative breast cancer: novel therapies and new directions. Maturitas 63:269–274PubMedCrossRef
25.
Zurück zum Zitat Corkery B, Crown J, Clynes M et al (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20:862–867PubMedCrossRef Corkery B, Crown J, Clynes M et al (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol 20:862–867PubMedCrossRef
26.
Zurück zum Zitat Inbar-Rozensal D, Castiel A, Visochek L et al (2009) A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer res 11:R78 Inbar-Rozensal D, Castiel A, Visochek L et al (2009) A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. Breast Cancer res 11:R78
Metadaten
Titel
Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients
verfasst von
Hiroko Masuda
Norikazu Masuda
Yoshinori Kodama
Masami Ogawa
Michiko Karita
Jun Yamamura
Kazunori Tsukuda
Hiroyoshi Doihara
Shinichiro Miyoshi
Masayuki Mano
Shoji Nakamori
Toshimasa Tsujinaka
Publikationsdatum
01.04.2011
Verlag
Springer-Verlag
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2011
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-010-1371-4

Weitere Artikel der Ausgabe 4/2011

Cancer Chemotherapy and Pharmacology 4/2011 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.